| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Eagle Pharmaceuticals, Inc. (EGRX) has 0 insiders with recent SEC Form 4 filings, including 5 buys and 16 sells. EGRX is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2017 | Meyers Pete A. | Chief Financial Officer | Buy | 350 | $71.49 | $25,020.77 | New | |
| May 19, 2017 | Pernock David | Pres. &Chief Comm. Officer | Buy | 255 | $79.69 | $20,320.95 | +35.9% | |
| May 16, 2017 | Pernock David | Pres. &Chief Comm. Officer | Buy | 200 | $82.24 | $16,448.00 | +39.1% | |
| Apr 25, 2017 | Proquest Investments Iv, L.P. | 10% Owner | Sale+OE | 54,180 | $88.38 | $4,788,481.95 | -76.6% | |
| Apr 3, 2017 | Proquest Investments Iv, L.P. | 10% Owner | Sell | 91,332 | $83.09 | $7,589,014.38 | -0.8% | |
| Mar 29, 2017 | Proquest Investments Iv, L.P. | 10% Owner | Sell | 106,468 | $83.01 | $8,837,576.19 | -0.9% | |
| Mar 23, 2017 | Krill Steven L. | EVP &Chief Scientific Officer | Sale+OE | 14,125 | $81.07 | $1,145,130.19 | -100% | |
| Mar 23, 2017 | Proquest Investments Iv, L.P. | 10% Owner | Sell | 1,200 | $83.05 | $99,657.00 | - | |
| Mar 22, 2017 | Edlin Richard A. | Director | Buy | 6,000 | $79.44 | $476,640.00 | +25.6% | |
| Mar 21, 2017 | Pernock David | Pres. &Chief Comm. Officer | Buy | 61 | $83.98 | $5,122.78 | +13.6% |